<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472417</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003683-39</org_study_id>
    <nct_id>NCT03472417</nct_id>
  </id_info>
  <brief_title>Partial Rebreathing in the Treatment of Migraine With Aura</brief_title>
  <acronym>CapnoMigra</acronym>
  <official_title>Partial Rebreathing in the Treatment of Migraine With Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BalancAir</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to test the efficacy of a partial rebreathing device in treating and/or preventing
      migraine pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Intensity Difference at 0 vs 2 hours post-treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>0-3 point scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Intensity Difference at 0 and 1 hour post-treatment (0-3 point scale)</measure>
    <time_frame>1 hour</time_frame>
    <description>0-3 point scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction/relief at 1 hour</measure>
    <time_frame>1 hour</time_frame>
    <description>percentage of study participants reporting no or mild pain 1 hour after first using the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction/relief at 2 hours</measure>
    <time_frame>2 hours</time_frame>
    <description>percentage of study participants reporting no or mild pain 2 hours after first using the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea Intensity Difference 0 vs 1 hour post-treatment</measure>
    <time_frame>1 hour</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea Intensity Difference 0 vs 2 hours post-treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photo - and/or phono-phobia Intensity Difference 0 vs 1 hour post-treatment</measure>
    <time_frame>1 hour</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photo - and/or phono-phobia Intensity Difference 0 vs 2 hours post-treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Disability Difference 0 vs 1 hour post-treatment</measure>
    <time_frame>1 hour</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Disability Difference 0 vs 2 hours post-treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>0-3 scale (0 = none, 1 = mild, 2= moderate, 3 =severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained pain freedom at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>percentage of study participants who are pain free 24 hours after device use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment preference vs. patient's normal treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>-2 to +2 scale ((-2 = much worse than normal treatment, - 1 = somewhat worse, 0 = no difference, +1 = somewhat better, +2 = much better))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aura symptoms aborted after one use of device</measure>
    <time_frame>20 minutes</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>through study completion (1 to 10 months)</time_frame>
    <description>Qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion (1 to 10 months)</time_frame>
    <description>Qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medicine use in 24 hours after device use</measure>
    <time_frame>24 hours</time_frame>
    <description>qualitative comparison</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>Active partial rebreathing device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dummy partial rebreathing device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active partial rebreathing device</intervention_name>
    <arm_group_label>Active partial rebreathing device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dummy partial rebreathing device</intervention_name>
    <arm_group_label>Dummy partial rebreathing device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Migraine with aura

          -  Attack frequency of between one and six migraine-with-aura attacks per month over the
             last six months

          -  Adults (18-60 years)

          -  Age at onset of migraine &lt; 50 years

          -  If taking migraine prophylactic drugs, the dosis must have been stable for &gt; 3 months

          -  Must speak and understand Danish

        Exclusion Criteria:

          -  - Cardiovascular disease, pulmonary disease, metabolic acid/base disorder, cancer,
             moderate and severe depression, anemia or other blood disease

          -  Chronic migraine, i.e. more than 15 headache days per month over the last three months

          -  Medication overuse headache

          -  More than six migraine-with-aura attacks per month

          -  Non-migraine headache on more than six days per month

          -  A typical duration between migraine-with-aura attacks of less than 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flemming W Bach, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pain and Headache Clinic, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

